HeartFlow (HTFL) Q2 2026: Revenue Growth Accelerates 48% Amid Plaque and FFRCT Momentum
HeartFlow’s second quarter demonstrated accelerating revenue growth driven by robust adoption of its AI-powered plaque and FFRCT diagnostic solutions. The company raised full-year guidance, reflecting confidence in expanding clinical utilization and market penetration. Ongoing innovation and clinical trial initiatives position HeartFlow for sustained growth and margin expansion.
Summary
- Market Penetration Expansion: Accelerating adoption of plaque analysis and durable FFRCT utilization underpin revenue momentum.
- Operational Leverage: Gross margin improved to 83.3%, driven by AI efficiencies and higher-margin product mix.
- Strategic Innovation Pipeline: Clinical trials targeting asymptomatic populations and new product launches support long-term growth.
Business Overview
HeartFlow, Inc. is a medical technology company specializing in AI-driven diagnostic solutions for coronary artery disease (CAD). Its core revenue streams derive from two main products: HeartFlow FFR CT Analysis, which provides lesion-specific fractional flow reserve assessments non-invasively, and HeartFlow Plaque Analysis, which quantifies coronary plaque burden. The company generates revenue primarily through usage-based models across hospitals and health systems, with a growing installed base of accounts driving recurring volume.
Performance Analysis
In Q2 2026, HeartFlow reported total revenue of $64.1 million, marking a 48% year-over-year increase and representing the fastest growth pace in eight quarters. U.S. revenue growth was particularly strong at 51%, fueled by increased case volumes and expanding customer adoption of both FFRCT and plaque analysis. The plaque product line (PLAC) exceeded expectations with $7.8 million in revenue, reflecting accelerating activations and physician utilization. FFRCT volumes remained durable with existing accounts maintaining steady utilization and new accounts ramping as anticipated.
Gross margin expanded significantly to 83.3%, up 770 basis points year-over-year, reflecting scale benefits, AI-driven automation efficiencies, and a higher mix of high-margin plaque revenue. Operating expenses increased but at a slower rate relative to revenue, resulting in improved operating leverage. Non-GAAP operating expenses were 96% of revenue, down from 102% a year earlier, and adjusted EBITDA losses narrowed, underscoring improving profitability dynamics.
- Broad-Based Revenue Drivers: Growth was supported by new account additions, ramping utilization, and underlying market expansion of coronary CT angiography (CCTA).
- Margin Expansion Levers: AI efficiency initiatives and volume leverage contributed materially to improved gross margins.
- Operating Expense Discipline: Investments in R&D and sales were balanced by cost controls, supporting a 600 basis point improvement in operating expenses as a percentage of revenue.
Overall, HeartFlow’s Q2 results reflect a scalable business model with accelerating commercial traction and margin expansion, laying a foundation for sustained growth and approaching profitability.
Executive Commentary
"The second quarter reflects the growing strength of HeartFlow's category leadership and unique AI technology platform for identifying, diagnosing, managing and treating coronary artery disease. The CCTA market for detecting CAD continues to grow rapidly and remains significantly under-penetrated, providing a strong backdrop for continued growth."
John Farquhar, President and Chief Executive Officer
"Our second quarter results demonstrated the increasing strength of the HeartFlow financial model. Forty-eight percent revenue growth, 770 basis points of gross margin expansion, and a 600 basis point improvement in operating expenses as a percentage of revenue. We remain disciplined in allocating incremental investment towards initiatives with a direct line of sight to revenue growth, product innovation, and addressable market expansion."
Vikram Verghese, Chief Financial Officer
Strategic Positioning
1. Accelerating Commercial Adoption of Plaque and FFRCT
HeartFlow’s installed base expanded rapidly with new account additions and increasing physician utilization. Plaque analysis activations exceeded expectations with utilization ramping ahead of plan, supported by strong clinical evidence of accuracy and reproducibility. FFRCT utilization remains stable across existing accounts while new accounts onboarded in 2025 continue to ramp in line with projections. This dual-product growth strategy enhances HeartFlow’s platform stickiness and deepens clinical integration.
2. Innovation Pipeline Driving Differentiation
The company launched HeartFlow Plaque Staging, a clinically validated risk stratification tool, expected to further accelerate plaque adoption. PCI Navigator, enabling interventional cardiologists to plan procedures with lesion-specific insights, is gaining traction and will see broader rollout in 2027. Autonomous Processing and PlaqueTracker initiatives, leveraging HeartFlow’s proprietary dataset of over 200 million annotated CCTA images, are on track to enhance efficiency and support midterm gross margin targets.
3. Expanding Addressable Market with Asymptomatic Clinical Trials
HeartFlow is initiating three randomized controlled trials (RCTs) targeting high-risk asymptomatic populations, aiming to expand its total addressable market by approximately $6 billion. These trials will leverage existing technology without requiring new FDA clearance and focus on demonstrating improved clinical outcomes and physician management, setting the stage for reimbursement and adoption in new patient segments before 2030.
4. Clinical Evidence as a Competitive Moat
With over 625 peer-reviewed publications and 200 clinical studies, HeartFlow maintains a leading evidence base supporting its AI diagnostics platform. Recent studies highlighted precision and reproducibility of plaque analysis and its superiority over calcium scoring alone. This robust data foundation underpins physician confidence and payer acceptance, reinforcing HeartFlow’s market leadership.
5. Financial Discipline Underpinning Path to Profitability
Despite increased investments in R&D and commercial expansion, HeartFlow improved operating leverage with non-GAAP operating expenses declining as a percentage of revenue. The company expects continued margin expansion driven by AI efficiencies and volume scale, targeting 85% non-GAAP gross margin midterm and cash flow profitability by mid-2028.
Key Considerations
HeartFlow’s Q2 performance and strategic initiatives highlight several important considerations for investors:
- Revenue Mix Evolution: The growing contribution from plaque analysis, a higher-margin product, is pivotal to margin expansion and long-term profitability.
- Utilization Dynamics: FFRCT utilization remains durable with a mature utilization opportunity estimated at one-third of CCTA volumes, while plaque applicability is broader at approximately 60% of CCTAs.
- Innovation Timing: Product rollouts such as PlaqueTracker and Autonomous Processing are expected to contribute to margin gains starting in 2027.
- Market Access and Reimbursement: Stable coverage levels near 78% and positive CMS reimbursement proposals support favorable economics in both hospital and physician settings.
- Investment Priorities: Continued disciplined spending on R&D, clinical trials, and commercial expansion balances growth with improving operating leverage.
Risks
Risks include potential delays in clinical trial outcomes or payer reimbursement for asymptomatic populations, competitive pressures from alternative diagnostic modalities, and ongoing patent litigation. Regulatory and reimbursement frameworks remain evolving, which could impact adoption rates and pricing dynamics. Execution risks around scaling autonomous processing and new product launches also warrant attention.
Forward Outlook
For Q3 2026, HeartFlow expects steady sequential growth building on its strong Q2 base, with seasonality factored into FFRCT volume assumptions. The company raised full-year 2026 revenue guidance to a range of $246 million to $250 million, reflecting 40% to 42% growth. Full-year plaque revenue guidance was increased to $29 million to $31 million, with activated plaque accounts projected to reach approximately 1,250 by year-end. Non-GAAP gross margin guidance was raised to approximately 82%, driven by AI efficiencies and product mix. Operating expenses as a percentage of revenue are expected to decline year-over-year, supporting a path toward profitability.
Takeaways
HeartFlow’s Q2 results solidify its leadership in AI-based coronary diagnostics, with accelerating adoption across its core FFRCT and emerging plaque products. The company’s innovation pipeline and clinical evidence base position it well to expand into larger patient populations, including asymptomatic individuals, unlocking significant new revenue opportunities. Operational improvements and AI-driven automation are driving margin expansion and improved operating leverage, reinforcing confidence in the midterm gross margin targets and profitability timeline. Investors should monitor execution on clinical trials, reimbursement developments, and autonomous processing rollout as key catalysts shaping future growth.
- Robust Growth and Margin Expansion: Accelerating revenue growth combined with 770 basis points gross margin improvement demonstrates scalable business strength.
- Strategic Innovation and Market Expansion: New product launches and RCTs targeting asymptomatic populations signal meaningful addressable market growth ahead.
- Profitability Trajectory: Disciplined expense management and AI efficiency initiatives underpin a credible path to cash flow profitability by mid-2028.
Conclusion
HeartFlow’s second quarter performance reflects strong commercial execution, innovation leadership, and improving financial dynamics. The company’s raised guidance and strategic investments highlight confidence in sustained growth and margin expansion. As HeartFlow advances its clinical programs and broadens market reach, it is well positioned to solidify its role as the AI operating system for coronary artery disease diagnostics.
Industry Read-Through
HeartFlow’s results underscore the growing adoption of AI-driven diagnostics in cardiovascular care, highlighting the expanding role of non-invasive imaging technologies like CCTA. The company’s progress in clinical validation and payer engagement provides a blueprint for other medtech firms pursuing AI-enabled platforms. Additionally, the emphasis on asymptomatic patient populations signals a broader industry shift toward earlier detection and preventive care, which could reshape diagnostic pathways and reimbursement models across cardiovascular and related specialties.